NEWS
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at Kidney Week 2024
Mallinckrodt presented data on TERLIVAZ (terlipressin) for hepatorenal syndrome (HRS) at Kidney Week 2024. The presentation featured a pooled analysis from Phase 3 trials (CONFIRM and REVERSE) examining treatment outcomes in HRS patients. Key findings showed that in patients listed for liver transplant at baseline, TERLIVAZtreatment resulted in 43% HRS-AKI reversal rate compared to 20% in the placebo group. The treatment also reduced the need for renal replacement therapy while maintaining similar liver transplant rates between groups. TERLIVAZ is the first FDA-approved product for improving kidney function in adults with HRS, a condition affecting approximately 42,000 Americans annually.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2354Followers
106Following
25KVisitors
Follow
Lnova : thanks for sharing
Lnova : $0.12 stock wow
Jaguar8 OP Lnova : This is in OTC
Lnova Jaguar8 OP : ah, gotcha. Ty
